No Data
No Data
Why Tempus AI Inc. (TEM) Soared Last Week
Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, IRhythm Technologies and SOPHiA GENETICS
TD Cowen Maintains Tempus AI(TEM.US) With Buy Rating, Cuts Target Price to $62
Press Release: Tempus to Report First Quarter 2025 Financial Results on May 6
Beyond The Numbers: 9 Analysts Discuss Tempus AI Stock
Shroomie : NO
Contender : after he run... it will fly
Shroomie : it just broke the 200 day... why sell now lol
Ps 23_1 : up up up…
Darrow Fields Ps 23_1 : bullish continuation wedge... shave off based on entry. if entry is good, hold. #Ark